Glucocorticoids are not always deleterious for bone

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Bone and Mineral Research

• Publication date

  2010-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jbmr.151PMID 20549703
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bone as an endocrine organ.

  2012cited by this paper
• Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration

  2010cited by this paper
• Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice

  2010cited by this paper
• Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

  2010cited by this paper
• Baseline Glucocorticoid Dose and Bone Mineral Density Response with Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-induced Osteoporosis

  2010cited by this paper
• Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance.

  2010cited by this paper
• The Amazing Osteocyte

  2010cited by this paper
• Oxidative stress stimulates apoptosis and activates NF-kappaB in osteoblastic cells via a PKCbeta/p66shc signaling cascade: counter regulation by estrogens or androgens.

  2010cited by this paper
• Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice.

  2010cited by this paper
• From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis.

  2010cited by this paper
• Glucocorticoid-Induced Autophagy in Osteocytes

  2010cited by this paper
• Cell Death

  2010cited by this paper
• Autophagy in mineralizing tissues: Microenvironmental perspectives

  2009cited by this paper
• Osteocyte Remodeling of the Perilacunar and Pericanalicular Matrix

  2009cited by this paper
• The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years.

  2009cited by this paper
• Estrogens Attenuate Oxidative Stress and the Differentiation and Apoptosis of Osteoblasts by DNA-Binding-Independent Actions of the ERα

  2009cited by this paper
• PKCδ signaling: A dual role in regulating hypoxic stress-induced autophagy and apoptosis

  2009cited by this paper
• Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

  2009cited by this paper
• Autophagy and cancer: dynamism of the metabolism of tumor cells and tissues.

  2009cited by this paper
• Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3β

  2009cited by this paper
• BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis.

  2009cited by this paper
• Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

  2009cited by this paper
• Autophagy in disease: a double-edged sword with therapeutic potential.

  2009cited by this paper
• Regulation mechanisms and signaling pathways of autophagy.

  2009cited by this paper
• Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases.

  2009cited by this paper
• Life and death partners: apoptosis, autophagy and the cross-talk between them

  2009cited by this paper
• Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy

  2009cited by this paper
• Starvation in the midst of plenty: making sense of ceramide-induced autophagy by analysing nutrient transporter expression.

  2009cited by this paper
• Sclerostin in Mineralized Matrices and van Buchem Disease

  2009cited by this paper
• Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

  2009cited by this paper
• Do osteocytes contribute to phosphate homeostasis?

  2009cited by this paper
• Giant osteoclast formation and long-term oral bisphosphonate therapy.

  2009cited by this paper
• The role of bone in phosphate metabolism.

  2009cited by this paper
• REACTIVE OXYGEN SPECIES AND GLUCOCORTICOID‐INDUCED HYPERTENSION

  2008cited by this paper
• Short-term effects of glucocorticoid therapy on biochemical markers of bone metabolism in Japanese patients: a prospective study

  2008cited by this paper
• Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization.

  2008cited by this paper
• Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice.

  2008cited by this paper
• Influence of glucocorticoid on bone in 3-, 6-, and 12-month-old rats as determined by bone mass and histomorphometry

  2008cited by this paper
• Genetic analysis and effect of triiodothyronine and prednisone trial on bone turnover in a patient with craniotubular hyperostosis.

  2008cited by this paper
• Autophagy fights disease through cellular self-digestion

  2008cited by this paper
• Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

  2008cited by this paper
• Safety of parathyroid hormone for the treatment of osteoporosis

  2008cited by this paper
• SOST/Sclerostin: An Osteocyte-Derived Inhibitor of Bone Formation that Antagonizes Canonical Wnt Signaling

  2008cited by this paper
• Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

  2007cited by this paper
• Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF

  2007cited by this paper
• Self-eating and self-killing: crosstalk between autophagy and apoptosis

  2007cited by this paper
• Glucocorticoid-induced osteoporosis: pathophysiology and therapy

  2007cited by this paper
• Dickkopf-1 is a master regulator of joint remodeling

  2007cited by this paper
• The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength.

  2007cited by this paper
• Skeletal Involution by Age-associated Oxidative Stress and Its Acceleration by Loss of Sex Steroids*

  2007cited by this paper
• Is long-term glucocorticoid therapy associated with a high prevalence of asymptomatic vertebral fractures?

  2007cited by this paper
• Evaluation of oxidative stress and effectiveness of low-dose glucocorticoid therapy on exacerbation of chronic obstructive pulmonary disease.

  2007cited by this paper
• Osteocytes as Dynamic Multifunctional Cells

  2007cited by this paper
• Osteocytes as multifunctional cells.

  2006cited by this paper
• Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density.

  2006cited by this paper
• Regulation of Intracellular Accumulation of Mutant Huntingtin by Beclin 1*

  2006cited by this paper
• Effect of Glucocorticoid Pretreatment on Oxidative Liver Injury and Survival in Jaundiced Rats with Endotoxin Cholangitis

  2006cited by this paper
• High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study.

  2006cited by this paper
• Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status.

  2006cited by this paper
• Shedding of lymphocyte function-associated antigen-1 (LFA-1) in a human inflammatory response.

  2006cited by this paper
• Wnt signalling in osteoblasts regulates expression of the receptor activator of NFκB ligand and inhibits osteoclastogenesis in vitro

  2006cited by this paper
• Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin.

  2006cited by this paper
• Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.

  2006cited by this paper
• Bone quality--the material and structural basis of bone strength and fragility.

  2006cited by this paper
• The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study.

  2005cited by this paper
• Glucocorticoid‐Treated Mice Have Localized Changes in Trabecular Bone Material Properties and Osteocyte Lacunar Size That Are Not Observed in Placebo‐Treated or Estrogen‐Deficient Mice

  2005cited by this paper
• Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression.

  2005cited by this paper
• Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment

  2005cited by this paper
• Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club

  2005cited by this paper
• Lysosomes and autophagy in cell death control

  2005cited by this paper
• Glucocorticoid pathways in chronic obstructive pulmonary disease therapy.

  2005cited by this paper
• Essential role of beta-catenin in postnatal bone acquisition.

  2005cited by this paper
• Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients.

  2005cited by this paper
• Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.

  2005cited by this paper
• Essential Role of β-Catenin in Postnatal Bone Acquisition*

  2005cited by this paper
• Ovariectomy induces oxidative stress and impairs bone antioxidant system in adult rats.

  2005cited by this paper
• Another way to die: autophagic programmed cell death

  2005cited by this paper
• The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death

  2005cited by this paper
• Mice Lacking the Integrin β5 Subunit Have Accelerated Osteoclast Maturation and Increased Activity in the Estrogen‐Deficient State

  2004cited by this paper
• LC3 conjugation system in mammalian autophagy

  2004cited by this paper
• Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist

  2004cited by this paper
• The skeletal effects of glucocorticoid excess override those of orchidectomy in mice.

  2004cited by this paper
• Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength.

  2004cited by this paper
• Apoptosis--a significant cause of bone cell death in osteonecrosis of the femoral head.

  2004cited by this paper
• Glucocorticoid-Induced Osteoporosis

  2004cited by this paper
• Effects of Low‐Dose Prednisone on Bone Metabolism

  2004cited by this paper
• Dentin matrix protein 1 expression during osteoblastic differentiation, generation of an osteocyte GFP-transgene.

  2004cited by this paper
• Oral glucocorticoid use is associated with an increased risk of fracture

  2004cited by this paper
• Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study.

  2004cited by this paper
• Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis.

  2004cited by this paper
• Role of apical caspases and glucocorticoid-regulated genes in glucocorticoid-induced apoptosis of pre-B leukemic cells.

  2003cited by this paper
• Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal.

  2003cited by this paper
• The natural history of sclerosteosis

  2003cited by this paper
• Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.

  2003cited by this paper
• Van Buchem disease: lifetime evolution of radioclinical features

  2003cited by this paper
• In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker.

  2003cited by this paper
• Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

  2002cited by this paper
• Rats with a glucocorticoid-induced catabolic state show symptoms of oxidative stress and spleen atrophy: the effects of age and recovery.

  2002cited by this paper
• A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population.

  2002cited by this paper
• Osteoblastic 11β‐Hydroxysteroid Dehydrogenase Type 1 Activity Increases With Age and Glucocorticoid Exposure

  2002cited by this paper

• Long-term clinical and bone mineral density changes of adult patients with sclerostin deficiency due to van Buchem disease: a follow-up study

  2025influential citation
• The Role of Sclerostin in Bone Diseases

  2022cites this paper
• The Genetic Architecture of High Bone Mass

  2020cites this paper
• Sost Haploinsufficiency Provokes Peracute Lethal Cardiac Tamponade without Rescuing the Osteopenia in a Mouse Model of Excess Glucocorticoids

  2019cites this paper
• Glucocorticoid Excess in Bone and Muscle

  2018cites this paper
• TGF-β Family Signaling in Connective Tissue and Skeletal Diseases.

  2017cites this paper
• Van Buchem disease

  2017cites this paper
• Sclerostin deficiency in humans.

  2017cites this paper
• Glucocorticoid induced osteoporosis and mechanisms of intervention

  2017cites this paper
• Maladie de Van Buchem

  2017cites this paper
• Role and mechanism of action of sclerostin in bone.

  2017cites this paper
• From disease to treatment: from rare skeletal disorders to treatments for osteoporosis

  2016cites this paper
• Sclerostin Blockade—A Dual Mode of Action After All?

  2016cites this paper
• Protection From Glucocorticoid‐Induced Osteoporosis by Anti‐Catabolic Signaling in the Absence of Sost/Sclerostin

  2016cites this paper
• Van Buchem's Disease.

  2016cites this paper
• Circulating Sclerostin in Bone Sclerosing Disorders

  2016cites this paper
• Hereditary Disorders of the Skeleton∗∗Chapter titles shaded in green indicate chapters dedicated predominantly to pediatric endocrinology content.

  2015cites this paper
• Decompressive surgery in a patient with hyperostosis corticalis generalisata for relief of cognitive disability and dysaesthesia

  2015cites this paper
• Glucocorticoid-induced osteoporosis: who to treat with what agent?

  2015cites this paper
• Van Buchem disease: Clinical, biochemical, and densitometric features of patients and disease carriers

  2013cites this paper
• Clinical Correlate : Van Buchem Disease

  2013cites this paper
• Friend or foe: high bone mineral density on routine bone density scanning, a review of causes and management.

  2013cites this paper
• A rare cause of facial nerve palsy in children: hyperostosis corticalis generalisata (Van Buchem disease). Three new pediatric cases and a literature review.

  2012cites this paper
• The Role of Sclerostin in the Pathophysiology of Sclerosing Bone Dysplasias

  2012influential citation
• Management of Glucocorticoid-Induced Osteoporosis

  2012cites this paper
• Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment.

  2012cites this paper
• Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnover

  2011cites this paper
• Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone.

  2011cites this paper